Reputational profile of a pharmaceutical company following the Covid-19 outbreak
A company operating on a global scale retained CRW to conduct integrity due diligence on a company in the pharmaceutical sector, in consideration of a business partnership.
Systematic analysis revealed that the company had a relatively negative public profile in relation to the Covid-19 pandemic and that, in the past, it had been involved in certain troubling issues, including being subject to sanctions in relation to irregularities in the marketing of drugs. Compared to its competitors, the company had a rather negative reputation in the media, but it emerged that it had been the subject of an adverse media campaign which steered information and the market to the advantage of certain pharmaceutical brands to the detriment of the company.
Our risk assessment enabled the client to take a risk-based and informed decision in relation to the business partnership.